| 18/04/2024 |
10:05 to 11:15 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
10:50 to 11:10 |
What is better? Dual or triple therapy in metastatic castration-sensitive prostate cancer? |
Speaker |
| 18/04/2024 |
10:05 to 11:15 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
11:10 to 11:15 |
Discussion |
Discussant |
| 18/04/2024 |
11:15 to 11:55 |
Golden Hall |
Clinical cases: metastatic castration-sensitive prostate cancer |
|
|
Discussant |
| 18/04/2024 |
12:40 to 13:55 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
12:40 to 13:00 |
PARP inhibitor treatment in advanced prostate cancer (single agent and combinations |
Speaker |
| 18/04/2024 |
12:40 to 13:55 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
13:00 to 13:05 |
Discussion |
Discussant |
| 18/04/2024 |
12:40 to 13:55 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
13:30 to 13:50 |
Best Sequencing in Castration-Resistant Prostate Cancer |
Speaker |
| 18/04/2024 |
12:40 to 13:55 |
Golden Hall |
Prostate Module - Metastatic Disease Session |
13:50 to 13:55 |
Discussion |
Discussant |
| 18/04/2024 |
15:15 to 15:55 |
Golden Hall |
Clinical cases: metastatic castration-resistant prostate cancer |
|
|
Discussant |
